Corticotropin-releasing factor (CRF), also known as corticotropin-releasing hormone (CRH), is a 41-amino acid peptide that serves as the primary regulator of the hypothalamic-pituitary-adrenal (HPA) axis and mediates stress responses throughout the brain. CRF neurons are distributed across several brain regions and play critical roles in stress-related disorders and neurodegenerative diseases.
CRF is the principal initiator of the stress response, coordinating behavioral, autonomic, and endocrine adaptations to threats. Dysregulation of CRF signaling has been implicated in depression, anxiety disorders, and neurodegenerative diseases [1].
| Property |
Value |
| Peptide |
CRH/CRF (41 amino acids) |
| Gene |
CRH (Chromosome 8q13) |
| Receptors |
CRHR1, CRHR2 |
| Primary location |
Paraventricular nucleus (PVN) |
| Peptide |
Gene |
Primary sites |
Function |
| CRF |
CRH |
PVN, amygdala |
Stress response |
| Urocortin 1 |
UCN |
Edinger-Westphal |
Stress, appetite |
| Urocortin 2 |
UCN2 |
Brainstem |
Stress, energy balance |
| Urocortin 3 |
UCN3 |
Perifornical area |
Stress, metabolism |
The PVN is the primary source of CRF:
- Parvocellular division: Main CRF cell group
- Projections: Median eminence (portal system)
- Control: Circadian and stress-driven
- Central nucleus: High CRF expression
- Bed nucleus of the stria terminalis: Stress integration
- Medial amygdala: Emotional processing
- Prefrontal cortex: Modulatory role
- Insula: Interoceptive stress
- Cingulate: Emotional awareness
- Locus coeruleus: Stress-norepinephrine interaction
- Raphe nuclei: Serotonin-CR interactions
- Nucleus tractus solitarius: Visceral stress inputs
| Property |
Details |
| Distribution |
Cortex, amygdala, cerebellum, pituitary |
| Signaling |
Gs-coupled, cAMP increase |
| Function |
Anxiety, stress response |
| Antagonists |
Pharmacological tools |
| Property |
Details |
| Distribution |
Hypothalamus, septum, brainstem |
| Signaling |
Gs and Gi-coupled |
| Function |
Stress coping, appetite |
| Ligands |
Urocortins > CRF |
- cAMP/PKA: Primary signaling cascade
- MAPK pathways: Cell survival, plasticity
- Calcium signaling: Neurotransmitter release
- Gene transcription: CREB activation
- Presynaptic: Modulates glutamate release
- Postsynaptic: Alters neuronal excitability
- Plasticity: Involved in stress-induced changes
CRF neurons orchestrate the stress response:
- CRF release → Pituitary ACTH → Adrenal cortisol
- Feedback → Hippocampus, hypothalamus
- Circadian rhythm → Morning peaks, evening troughs
CRF mediates:
- Arousal: Increased vigilance
- Fear processing: Threat assessment
- Memory enhancement: Stressful memories
- Motor activity: Behavioral activation
CRF influences:
- Heart rate: Through brainstem circuits
- Blood pressure: Sympathetic activation
- Digestion: Autonomic modulation
- Thermoregulation: Stress-induced hyperthermia
CRF dysregulation contributes to AD pathology:
- Chronic stress: Elevated cortisol in AD
- Hippocampal vulnerability: CRF toxicity to hippocampal neurons [2]
- Amyloid interactions: CRF modulates Aβ processing
- Tau phosphorylation: Stress kinases activate tau pathology
PD involves CRF system alterations:
- Stress vulnerability: May accelerate PD progression
- Levodopa response: CRF modulates dopaminergic function
- Non-motor symptoms: Depression, anxiety in PD
- Neuroinflammation: CRF affects microglial activation [3]
ALS shows CRF system changes:
- HPA axis dysfunction: Documented in ALS patients
- Stress response: Altered cortisol regulation
- Motor neuron vulnerability: Excitotoxicity interactions
- Autonomic dysfunction: CRF-autonomic connections [4]
HD involves CRF alterations:
- HPA axis hyperactivity: Documented in HD
- Stress sensitivity: Exacerbates symptoms
- Neurodegeneration: CRF contributes to striatal vulnerability
- Behavioral symptoms: Anxiety, depression [5]
¶ Depression and Anxiety
CRF is central to stress-related disorders:
- CRF elevation: State and trait markers
- CRHR1 antagonists: Therapeutic potential
- Treatment effects: SSRIs reduce CRF
| Compound |
Development status |
Indication |
| Pexacerfont |
Discontinued |
Anxiety, depression |
| Verucerfont |
Clinical trials |
PTSD, anxiety |
| BMS-986020 |
Preclinical |
Stress disorders |
- Peptide analogs: Stable CRF agonists/antagonists
- Gene therapy: Local CRF modulation
- Seed-based approaches: Natural compounds
- Lifestyle interventions: Stress reduction
- SSRIs/SNRIs: Reduce CRF expression
- Exercise: Normalize HPA axis
- Meditation: Stress reduction
- Sleep optimization: Cortisol regulation
- Serum cortisol: Morning and evening levels
- ACTH: Pituitary function
- DEX/CRH test: HPA axis assessment
- Salivary cortisol: Diurnal rhythm
- CSF CRF: Disease state marker
- Imaging: CRHR1 PET ligands
- Genetic markers: CRH polymorphisms
- Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981
- Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuronal death. Biol Psychiatry. 2000
- Jellinger KA. Neurobiology of anxiety and stress-related disorders. J Neural Transm Suppl. 2003
- Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013
- Du X, Pang TY. Dysregulation of the hypothalamic-pituitary-adrenal axis in Huntington's disease. Neurobiol Dis. 2015